RAMM Pharma Corp. RAMM
CNSX
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 186.20K | 139.00K | 153.40K | 436.50K | 642.90K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 186.20K | 139.00K | 153.40K | 436.50K | 642.90K |
| Cost of Revenue | 176.10K | 46.20K | 55.30K | 95.60K | 642.50K |
| Gross Profit | 10.20K | 92.80K | 98.10K | 340.90K | 300.00 |
| SG&A Expenses | 701.20K | 692.90K | 772.60K | 1.39M | 687.40K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 4.40K | 2.90K | 1.10K | 45.90K | 3.30K |
| Total Operating Expenses | 881.60K | 742.00K | 829.00K | 1.53M | 1.33M |
| Operating Income | -695.30K | -603.00K | -675.60K | -1.09M | -690.40K |
| Income Before Tax | -635.60K | -202.00K | -547.00K | -5.15M | -380.70K |
| Income Tax Expenses | -- | -- | -- | 7.70K | -- |
| Earnings from Continuing Operations | -635.60K | -202.00K | -547.00K | -5.16M | -380.70K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -635.60K | -202.00K | -547.00K | -5.16M | -380.70K |
| EBIT | -695.30K | -603.00K | -675.60K | -1.09M | -690.40K |
| EBITDA | -616.30K | -540.20K | -600.00K | -1.02M | -580.20K |
| EPS Basic | -0.01 | 0.00 | 0.00 | -0.04 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| EPS Diluted | -0.01 | 0.00 | 0.00 | -0.04 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| Average Basic Shares Outstanding | 119.39M | 119.39M | 119.39M | 119.39M | 119.39M |
| Average Diluted Shares Outstanding | 119.39M | 119.39M | 119.39M | 119.39M | 119.39M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |